非小细胞肺癌新辅助免疫治疗在临床中的应用进展

肺癌的发病率和病死率普遍较高,严重威胁大众身体健康。目前,手术仍然是对能够切除的非小细胞肺癌（NSCLC）的良好干预策略。免疫检测点类的抑制药物的出现极大程度上改变了NSCLC的干预效果。随着研究深入,免疫检查点抑制剂在治疗NSCLC的安全性和可行性方面也有着优异的表现,但仍缺乏远期预后评估,以及公认合理的治疗方案和疗程等。该文将阐述新辅助免疫治疗可切除的NSCLC的发展过程、作用机制及研究现状。

Advances in the application of neoadjuvant immunotherapy for non-small cell lung cancer

The incidence and mortality of lung cancer are generally high, which severely threatens the public health. Surgery remains an excellent intervention strategy for resectable non-small cell lung cancer (NSCLC). The emergence of immune checkpoint inhibitors has greatly changed the intervention effectiveness of NSCLC. As demonstrated by in-depth studies, immune checkpoint inhibitors exhibit high safety and feasibility in the treatment of NSCLC. However, there is still a lack of long-term evaluation of these drugs and consensus on the treatment regimens and the course of treatment. This review will elucidate the development, mechanism and research status of the neoadjuvant immunotherapy for resectable NSCLC.